Vioxx news from FierceBiotech
NewsMerck wins the 'silver' for worst news week
WBB Securities analyst Steve Brozak has issued a symbolic "silver medal" to Merck for worst news week. In a triple whammy rarely accomplished in the drug world, Merck had two experimental Read more...
ALSO NOTED: US Oncology's CFO retires; Profits rise at Novartis, Merck, Lilly; and much more...
> US Oncology's CFO Rick McCook is resigning to explore opportunities in a retail or manufacturing business. Read more...
ALSO NOTED: Isotechnika reports psoriasis success; Romark enrolls hep C patients; and much more...
> Isotechnika's ISA247 has demonstrated significant efficacy against psoriasis. Report > Romark Laboratories Read more...
Risk averse? Not us, says top FDA official
Is a rising tide of risk aversion at a post-Vioxx FDA behind the agency's anemic approval record? No way, say the FDA's Read more...
2008 NME approvals no better than last year?
In 2007, there was much ado about the slow pace of new molecular entity (NME) approvals. Though over 200 drugs were approved in 2007, only 19 of Read more...
ALSO NOTED: BMS falls prey to subprime crisis;AZ cuts 200 U.K. workers;much more...
What's a drugmaker doing, investing in securities at least partly backed by subprime mortgages? Ask Bristol-Myers Squibb, which took a $275 million write-down on so-called "auction rate securities" Read more...
ALSO NOTED: Cardiome awaits FDA decision; Congress to investigate Vytorin scandal; and much more...
> Cardiome is awaiting a critical FDA decision on its drug vernakalant. Report > It seems that many black U.S. residents Read more...
ALSO NOTED: Big Pharma rethinks animal testing; FDA extends telavancin review; and much more...
> In a move that will please animal rights activists, a number of pharmaceutical companies have determined that they will no longer conduct acute toxicity tests. They say that new technology has Read more...
FDA more friendly to approvable than approved
You've probably already heard that FDA approvals took a nasty dive last year, with analysts Read more...
'07's drug approval record raises worries
The paucity of NME approvals by the FDA last year--a miserly 16, one of the worst records in decades--is attracting worried Read more...
| Press ReleasesPRESS RELEASE: Merck Agreement to Resolve U.S. VIOXX Product Liability Lawsuits Merck Agreement to Resolve U.S. VIOXX® Product Liability Lawsuits Agreement Provides for $4.85 Billion Payment WHITEHOUSE STATION, N.J., Nov. 9, 2007 - Merck & Co., Inc. today announced Read more... PRESS RELEASE: Cuomo, Bloomberg Sue Maker of Vioxx for Hiding Drug's Risks Cuomo, Bloomberg Sue Maker of Vioxx for Hiding Drug's Risks FirstTime State and City Bring Joint Action to Fight Medicaid Fraud Suit claims Merck & Co. endangered patients, cost Medicaid Read more... PRESS RELEASE: New Jersey High Court Denies Nationwide Class-Action Status to Insurance Companies Seeking VIOXX Reimbursements New Jersey High Court Denies Nationwide Class-Action Status to Insurance Companies Seeking VIOXX® Reimbursements WHITEHOUSE STATION, N.J., Sept. 6, 2007 - Merck & Co., Inc. is pleased that Read more... |
Get more Vioxx coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight